Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 03:22 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of Micro Dose Ambrisentan in Hospitalized Patients With Respiratory Insufficiency Due to COVID-19
NCT04771000 · Noorik Biopharmaceuticals AG · PHASE2 · terminated · last registry update 2023-03-21 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Lack of recruitment” | – | Registry record, Noorik Biopharmaceuticals AG |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against EDNRB within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-03-12Results posted on the registry: University of California, Los Angeles, Macitentan (NCT05373108)
- 2024-03-08Also stopped (withdrawn): University of Maryland, Baltimore, Macitentan 10mg (NCT05946811)
- 2024-03-05Results posted on the registry: United Therapeutics, IV Remodulin + Placebo (NCT02261883)
- 2024-03-05Also stopped (terminated): United Therapeutics, IV Remodulin + Placebo (NCT02261883)
- 2024-02-20Also stopped (withdrawn): University of Missouri-Columbia, Hyperinsulinemic, euglycemic infusion (NCT05518422)
- 2024-01-03Also stopped (terminated): United Therapeutics, treprostinil (NCT00439946)
- 2024-01-03Also stopped (terminated): United Therapeutics, treprostinil sodium (NCT00643604)
- 2023-12-19Also stopped (withdrawn): United Therapeutics, treprostinil sodium + Placebo (NCT01884038)
- 2023-11-13Results posted on the registry: Actelion, FDC macitentan/tadalafil + Macitentan 10 mg (NCT03904693)
- 2023-10-31Results posted on the registry: University of Mississippi Medical Center, Sildenafil 100 mg + Bosentan 125 mg (NCT04770155)
- 2023-10-31Also stopped (terminated): University of Mississippi Medical Center, Sildenafil 100 mg + Bosentan 125 mg (NCT04770155)
- 2023-10-18Results posted on the registry: Bastiaan Driehuys, Hyperpolarized 129Xenon gas (NCT03367312)
- 2023-08-23Results posted on the registry: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA, Sotatercept + Placebo (NCT04576988)
- 2023-07-14Phase 3 first posted: University of Maryland, Baltimore, Macitentan 10mg (NCT05946811)
- 2023-04-19Results posted on the registry: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA, Placebo + Sotatercept (NCT03496207)
- 2023-04-11Results posted on the registry: Actelion, Macitentan (NCT02060721)
- 2023-03-21Results posted on the registry: Idorsia Pharmaceuticals Ltd., Aprocitentan 12.5 mg + Aprocitentan 25 mg (NCT03541174)
- 2023-03-07Results posted on the registry: Actelion, macitentan 10 mg (NCT03775421)
- 2023-03-07Also stopped (terminated): Actelion, macitentan 10 mg (NCT03775421)
- 2023-02-10Results posted on the registry: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA, Sotatercept (NCT03738150)
- 2022-12-30Results posted on the registry: GlaxoSmithKline, Ambrisentan (NCT01342952)
- 2022-11-23Also stopped (withdrawn): Idorsia Pharmaceuticals Ltd., Aprocitentan 25 mg + Placebo (NCT04162366)
- 2022-11-04Results posted on the registry: Actelion, macitentan 10 mg (NCT03714815)
- 2022-09-13Results posted on the registry: Actelion, Macitentan 10 mg + Placebo (NCT03153137)
- 2022-06-29Phase 3 first posted: RenJi Hospital, Ambrisentan (NCT05437224)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision